With Maverick now in Takeda’s hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech

James Scibetta

→ Another CEO opportunity has presented itself for James Scibetta, the chief executive of Maverick Therapeutics when Takeda ponied up $525 million in March to buy its T cell collaborator and integrate the staff into the R&D unit. Scibetta

Click to view original post